Close Menu

Veracyte

Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.

The genomic testing company's total revenues were down to $17.5 million in the quarter, although its genomic testing volume increased 14 percent.

The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today. 

Among its business highlights for the quarter, the firm established coverage for the Afirma genomic sequencing classifier by all major insurance plans.

The genomic test is designed to identify benign thyroid nodules in patients with indeterminate fine needle aspiration biopsy results.

The company missed analyst estimates on the top line, but beat expectations for loss per share during the quarter.

The firm touted recent Blues coverage decisions for the Afirma thyroid cancer test, and final Medicare coverage policies for the Percepta lung cancer test.

The firm said that the new coverage for its Afirma thyroid cancer test makes it a medically necessary benefit for nearly 24 million Blues plan members.

Veracyte said that Quest’s access to half of the physicians and hospitals in the US will provide patients with broader access to the Afirma GEC.

The firm said it expects that Noridian will similarly confirm its draft local coverage determination, bringing coverage for Percepta to around 35 million.

Pages

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.